Enstilar is a fixed-dose combination medication for the topical treatment of plaque psoriasis, integrating the therapeutic advantages of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid).

How to Use Enstilar

Administration Method

Once-daily Dosing Principle: Apply Enstilar foam to the affected areas once daily, for a maximum duration of 4 weeks. Discontinue treatment once the condition is under control.

Preparation Before Use: Shake the medication can thoroughly before use. Apply the medication evenly to the plaque psoriasis lesions and gently massage until absorbed.

Dosage Control: The total usage should not exceed 60 grams every 4 days.

Precautions for Use

Do not use occlusive dressings unless instructed by a healthcare provider.

Avoid use on the face, groin, or axillae (armpits), or avoid use if skin atrophy is present at the treatment site.

This product is for external use only. Do not take it orally, or use it in the eyes or vagina.

Wash hands after applying the medication.

Dosage Adjustment of Enstilar

Routine Dosage Management

The recommended median weekly dosage is 25 grams, which should be adjusted individually based on the patient’s specific condition and treatment response.

Adjustment for Special Cases

Long-term Usage Regimen: After the initial 4-week once-daily treatment, the regimen can be switched to twice-weekly (on non-consecutive days) use, for a maximum duration of 52 weeks.

Adjustment for Suboptimal Efficacy: If a decrease in efficacy occurs, resume once-daily treatment for a continuous 4-week period.

Treatment Course Monitoring

Regularly assess the efficacy during treatment. Discontinue treatment once satisfactory control of the condition is achieved to avoid unnecessary long-term use.

Administration of Enstilar in Special Populations

Pediatric Patients

The efficacy of Enstilar in the treatment of mild to severe plaque psoriasis has been established in pediatric patients aged 12 to 17 years.

Children under 12 years of age are particularly susceptible to systemic adverse reactions due to their higher ratio of skin surface area to body weight.

The efficacy of Enstilar foam in pediatric patients under 2 years of age has not been established.

Patients with Hepatic Impairment

Avoid using Enstilar foam in patients with clinical or laboratory evidence of liver disease, as this may increase the risk of metformin-associated lactic acidosis.